

[1*R*-(1 α ,4 β ,5 α ,7*R**)]-7-Bromo-4-isopropyl-1-methylbicyclo[3.1.1]heptan-6-one [(+)-7] and [1*S*-(1 α ,4 β ,5 α ,7*R**)]-7-Bromo-4-isopropyl-1-methylbicyclo[3.1.1]heptan-6-one [(+)-19b]. A solution of 293 mg of a crude 19c-29a keto ester mixture (from a cyclization of 478 mg (1.5 mmol) and esters 28) and 1 N potassium hydroxide in 15 mL of methanol and 5 mL of water was refluxed for 2 h. It was poured into 5% sodium hydroxide solution and extracted with ether. The aqueous solution was acidified with 6 N hydrochloric acid and extracted exhaustively with ether. The extract was washed with brine, dried, and evaporated. The residual mixture (247 mg) of acids 19d and 29b [IR (CCl₄) (OH) 3100-3400 (m), (C=O) 1787 (s), 1701 (s) cm⁻¹] and 0.05 mL of dimethylformamide were dissolved in 1 mL of dry benzene, and 0.5 mL (5.9 mmol) of oxalyl chloride was added dropwise at 0 °C. The solution was stirred at room temperature for 1 h and then evaporated. A solution of the residue in 5 mL of dry bromotrichloromethane was added dropwise over a 15-min period to a refluxing mixture of 209 mg (1.4 mmol) of sodium 1-oxypyridine-2-thiolate and 13 mg (0.12 mmol) of γ -(dimethylamino)pyridine in 10 mL of dry bromotrichloromethane. Refluxing was continued for 2 h, and the resultant, light orange suspension was filtered through Celite. The filtrate was evaporated, and the residual oil was dissolved in ether. The solution was washed with water and brine, dried, and evaporated. MPLC of the residue and elution with 40:1 petroleum ether-ethyl acetate provided 44 mg (12%) of liquid bromo ketone 7: [α]_D²³ +59.9° (CHCl₃, c = 0.60); CD_{max} [θ]₂₉₃²¹ +3212° (CHCl₃, c = 0.10); IR and ¹H NMR spectrally identical with the above sample of racemic ketone 7.

Anal. Calcd for C₁₁H₁₇OBr: C, 53.89; H, 6.99. Found: C, 54.24; H, 7.07.

Further elution afforded 81 mg (22%) of colorless, liquid bromo ketone 19b: [α]_D²³ +7.1 (CHCl₃, c = 0.70); CD_{max} [θ]₂₉₃²¹ +2444 (CHCl₃, c = 0.10); IR (CCl₄) (C=O) 1790 (s) cm⁻¹; ¹H NMR δ 0.93, 0.94 (d, 3 each, *i*-Pr methyls), 1.17 (s, 3, 1-Me), 1.5-2.3 (m, 6,

methylene, methines), 3.28 (s, 1, H-5), 4.41 (s, 1, H-7); ¹³C NMR δ 16.9 (1-Me), 19.6, 19.8 (*i*-Pr methyls), 20.3 (C-3), 32.2 (*i*-Pr CH), 39.2 (C-2), 47.3 (C-4), 52.0 (C-7), 67.1 (C-1), 69.4 (C-5), 212.1 (C=O).

Anal. Calcd for C₁₁H₁₇OBr: C, 53.89; H, 6.99 Found: C, 53.99; H, 7.11.

Bromo ketone 19b semicarbazone: mp 201-202 °C (EtOH).

Acknowledgment. P.M. expresses his gratitude to the Consejo Nacional de Investigaciones Cientificas y Tecnológicas (Argentina) for a 1986-1988 postdoctoral fellowship.

Registry No. 1, 499-75-2; (\pm)-2, 124355-77-7; (\pm)-3, 124439-20-9; (\pm)-4, 124355-78-8; (\pm)-5, 124355-79-9; (\pm)-6, 124355-80-2; 7 (isomer 2), 124379-63-1; (\pm)-7, 124508-22-1; (\pm)-8, 124355-81-3; 9, 124355-82-4; (\pm)-10a, 124355-83-5; (\pm)-10b, 124355-98-2; (\pm)-10c, 124355-99-3; (\pm)-10d, 124356-00-9; (\pm)-10e, 124439-22-1; (\pm)-10f, 124356-01-0; 11a, 124379-64-2; 11b, 124379-66-4; 11c, 124379-67-5; (\pm)-12a, 124379-65-3; (\pm)-12b, 124379-68-6; 13a, 2862-86-4; (\pm)-13b, 124356-02-1; (\pm)-13c, 124356-03-2; (\pm)-13d, 124356-04-3; (\pm)-13e, 124356-05-4; (\pm)-14a, 124355-84-6; (\pm)-14b, 124356-06-5; (\pm)-14c, 124356-07-6; (\pm)-15, 124355-85-7; (\pm)-16, 124355-86-8; (\pm)-17, 124355-87-9; 19b, 124355-88-0; 19b semicarbazone, 124356-12-3; 19c, 124356-08-7; 19c semicarbazone, 124356-17-8; 19d, 124356-09-8; (\pm)-20a, 124355-89-1; (\pm)-21, 124355-90-4; 22, 124355-91-5; 23a (isomer 1), 124355-92-6; 23a (isomer 2), 124356-18-9; 24a, 124355-93-7; 24b, 104857-78-5; 25 (isomer 1), 124355-94-8; 25 (isomer 2), 124439-26-5; 26a, 124439-21-0; 26b, 124439-23-2; 26c, 124356-10-1; 26d, 124439-24-3; 27, 124355-95-9; 28, 124355-96-0; 29a, 124355-97-1; 29b, 124356-11-2; i, 22081-48-7; (\pm)-iia, 124356-13-4; (\pm)-iib, 124356-14-5; (\pm)-iic, 124356-15-6; (\pm)-iid, 124439-25-4; (\pm)-iiaa, 124379-69-7; (\pm)-iibb, 124379-69-7; (\pm)-iv, 124356-16-7; ethyl trichloroacetate, 515-84-4; carvomenthone, 5206-83-7; isocarvomenthone, 7065-48-7.

Synthesis of

2,3-Dihydro-8-(3-hydroxy-3-methylbut-1-enyl)-7-methoxy-2-phenyl-4*H*-1-benzopyran-4-one: A Novel Structure for Falciformin

Virinder S. Parmar,* Sandhya Gupta, Rakesh K. Sharma, and Varun K. Sharma

Department of Chemistry, University of Delhi, Delhi-110 007, India

Received May 3, 1989

Synthesis of 2,3-dihydro-8-(3-hydroxy-3-methylbut-1-enyl)-7-methoxy-2-phenyl-4*H*-1-benzopyran-4-one (1) has been achieved in order to verify the proposed structure of falciformin, a new constituent of *Tephrosia falciformis*. The melting point and spectral characteristics of synthetic 1 are not consistent with those reported for the natural sample, thereby showing that the proposed structure is erroneous. Based on the data reported for the natural product, the new structure 2,3-dihydro-5-(1,1-dimethyl-2-hydroxyprop-2-enyl)-6-methoxy-2-phenyl-4*H*-1-benzopyran-4-one (4) is tentatively proposed for falciformin. The mass spectral fragmentation patterns of 1 and 4 are discussed in detail in support of their structures.

2,3-Dihydro-2-phenyl-4*H*-1-benzopyran-4-ones occur abundantly in plants and exhibit different biological activities, e.g. spasmolytic,¹ cytotoxic,² antihepatotoxic,³ and

antidiabetic (antigalactosemic cataract).⁴ Among acyclic isopentenylated flavonoids, those possessing 3-methyl-

(1) (a) Berger, H.; Holler, H. *Chem. Abstr.* 1958, 52, 3267; *Sci. Pharm.* 1957, 25, 172. (b) Rossi, G. V.; Packman, E. W.; Goldberg, M. E. *Am. J. Pharm.* 1957, 129, 89.

(2) (a) Lasswell, W. L.; Hufford, C. D. *J. Org. Chem.* 1977, 42, 1295. (b) Huang, M. T.; Wood, A. W.; Newmark, H. L.; Sayer, J. M.; Yagi, H.; Jerina, D. M.; Conney, A. M. *Carcinogenesis* 1983, 4, 1631.


(3) (a) Hahn, G.; Lehmann, H. D.; Kurten, M.; Hebel, H.; Vogel, G. *Chem. Abstr.* 1968, 69, 58230; *Arzneim. Forsch.* 1968, 18, 698. (b) Machicao, F.; Sonnenbichler, J. *Hoppe-Seyler's Z. Physiol. Chem.* 1977, 358, 141. (c) Wagner, H.; Haerhammer, L.; Muenster, R. *Chem. Abstr.* 1968, 69, 96396; *Arzneim. Forsch.* 1968, 18, 688. (d) Schnabel, R.; Sonnenbichler, J.; Zillig, W. *FEBS Lett.* 1982, 150, 400.

but-2-enyl and 1,1-dimethylprop-2-enyl as substituents are fairly common in nature, but there are very few instances when a 3-hydroxy-3-methylbut-1-enyl alkyl chain is present on the flavonoid skeleton. Falciformin, which is the only example of a 2,3-dihydro-2-phenyl-4*H*-1-benzopyran-4-one having this substituent, has recently been isolated⁵ from the pods of *Tephrosia falciformis*. Based on its spectral characteristics alone, it was formulated as 2,3-dihydro-8-(3-hydroxy-3-methylbut-1-enyl)-7-methoxy-2-phenyl-4*H*-1-benzopyran-4-one (1). However it is surprising that the olefinic protons, which are not magnetically equivalent⁶ appear as a singlet at δ 6.86. The detailed IR, UV (with shift reagents), and ¹³C NMR spectral data for the natural compound were not reported. The MS data reported for the natural sample were not explained in terms of the proposed structure 1. The present synthesis shows that the structure previously assigned to falciformin is not correct and suggests a revised structure 4 for it on the basis of the reported spectral data.

Results and Discussion

The base-catalyzed cyclization of 1-[2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-phenylprop-2-enone⁸ afforded a single compound in 70% yield, the spectral data of which were compatible with the structure 2,3-dihydro-7-methoxy-8-(3-methylbut-2-enyl)-2-phenyl-4*H*-1-benzopyran-4-one (2). The complete synthesis of flavanone (2) has not been reported thus far.⁹ Treatment of 2 with MCPBA in dry chloroform gave the hitherto unknown epoxide 3, the structure of which was fully established from its IR, UV, NMR, and mass spectral data.¹¹ The base-mediated opening of the epoxide ring in 3 yielded 1, the structure of which is fully established from its various spectral data.

The synthetic 1 showed considerable differences in its melting point and spectral data from those reported⁵ for



the natural sample of falciformin. The synthetic 1 melted at 178–179 °C, whereas the melting point reported for the natural sample⁵ is 108 °C. The UV absorption spectrum of synthetic 1 had λ_{max} at 315 and 232 (sh) nm, whereas the reported⁵ absorptions for the natural sample are at 260 and 290 nm. Further, the authors⁵ reported that the UV absorption maxima for the natural sample did not undergo any change on addition of alkali, but the natural specimen of falciformin, kindly supplied to us by Dr. Khan,⁵ was found to undergo a bathochromic shift to 325, 260, and 230 nm on addition of NaOH; it also exhibited significant bathochromic shifts in presence of AlCl₃ and NaOMe. However, the UV spectrum of our synthetic 1 did not undergo any change on addition of NaOH, NaOMe, or AlCl₃.

The ¹H NMR spectrum of synthetic 1 also showed considerable difference from that of falciformin⁵ in the chemical shift values of the alkyl side chain protons. Whereas it was reported that the olefinic protons of falciformin⁵ appear as a singlet at δ 6.86, thus being accidentally equivalent, in synthetic 1 they appeared merged at different chemical shift values, δ 4.30–5.55, as a multiplet for H-2 and H-2'' and a multiplet between δ 7.00 and 7.90 for the H-1'', H-5, and B ring protons. Also the natural sample of falciformin exhibited a singlet (6 H) at δ 1.38 for the *gem*-dimethyl group,⁵ whereas our synthetic 1 showed these protons as two singlets (3 H each) at δ 1.29 and 1.42. The mass spectral data reported⁵ for the natural sample were markedly different from that of our synthetic 1 (Chart I). The base peak was reported for the natural sample at *m/z* 201, but our synthetic 1 did not show any such fragment; on the other hand, the base peak observed for our synthetic 1 was at *m/z* 161 and the natural sample had no such fragment. Many other peaks observed in the MS of two samples were different.

(4) (a) Varma, S. D.; Kinoshita, J. H. *Biochem. Pharmacol.* **1976**, *25*, 2505. (b) Varma, S. D.; Kinoshita, J. H. *Biochim. Biophys. Acta* **1974**, *338*, 632. (c) Varma, S. D.; Mikuni, I.; Kinoshita, J. H. *Science* **1975**, *188*, 1215.

(5) Khan, H. A.; Chandrasekharan, I.; Ghanim, A. *Phytochemistry* **1986**, *25*, 767. No degradative evidence was reported for falciformin. Copies of the spectra could not be obtained from the authors; however, a very small amount of the natural sample was sent by them which was barely sufficient to run UV spectrum in presence of shift reagents (NaOH, NaOMe, AlCl₃).

(6) We have found, in literature,⁷ a few polyphenolic compounds carrying the same C₅ side chain on the heterocyclic nucleus and in all the cases the olefinic protons appear as trans doublets (*J* = 16–17 Hz). For the natural sample of falciformin also, Khan et al.⁵ report the trans double bond from the IR absorption at 970 cm⁻¹, but report a singlet at δ 6.86 in its ¹H NMR spectrum for these protons.

(7) (a) Gray, A. I.; Waigh, R. D.; Waterman, P. G. *J. Chem. Soc., Perkin Trans. 1* **1975**, 488. (b) Shibata, S.; Noguchi, M. *Phytochemistry* **1977**, *16*, 291. (c) Chan, W. R.; Taylor, D. R.; Willis, C. R. *J. Chem. Soc. C* **1967**, 2540. (d) Kis, Z.; Closse, A.; Sigg, H. P.; Hruban, L.; Snatzke, G. *Helv. Chim. Acta* **1970**, *53*, 1577.

(8) Khanna, R. N.; Khanna, P. L.; Manchanda, V. P.; Seshadri, T. R. *Indian J. Chem.* **1973**, *11*, 1225.


(9) It has, however, been prepared earlier¹⁰ by the cyclization of the corresponding naturally occurring chalcone, derricin, using sodium hydroxide. The melting point, ¹H NMR, and IR data¹⁰ differed slightly from those of our 2. The peaks in the MS of two were observed at the same *m/z* values. The earlier authors¹⁰ had neither reported the characteristic peaks for the C-2 and C-3 protons in the ¹H NMR spectrum nor the UV spectral absorptions, both of these are characteristic for this class of compounds. The structure of our 2 has been well supported by its UV, NMR, and mass spectral data.

(10) Nascimento, M. C.; Mors, W. B. *Phytochemistry* **1972**, *11*, 3023.

(11) The IR spectrum of 3 exhibited characteristic¹² epoxide band at 1240 cm⁻¹ and the ¹H NMR absorption for the C-1'' and C-2'' protons were also in order for similar C₆-epoxy side chain.¹²

(12) (a) Bohlmann, F.; Jakupovic, J. *Phytochemistry* **1979**, *18*, 1367. (b) Austin, P. W.; Seshadri, T. R.; Sood, M. S.; Paul, V. *Tetrahedron* **1968**, *24*, 3247.

Chart II. Mass Spectral Fragmentation of
2,3-Dihydro-5-(1,1-dimethyl-2-hydroxyprop-2-enyl)-6-methoxy-2-phenyl-4H-1-benzopyran-4-one (4)



structure 1, λ_{max} values for falciformin should have been observed at higher wavelengths; the synthetic 1 had λ_{max} at 315 and 232 (sh) nm. Also the bathochromic shifts undergone by the UV spectrum of the natural sample with alkali and $AlCl_3$ are explained by structure 4 as there is an enolic, chelated hydroxyl function. Further support for the chelated carbonyl function in falciformin is provided by its IR absorption⁵ at 1650 cm^{-1} ; normally, the carbonyl frequency in chromanones is around 1680 cm^{-1} . Further evidence in support of our proposed structure 4 is provided by the expected mass spectral fragmentation pathways (cf. Chart II),¹⁸ which explain all the peaks reported for the

natural sample of falciformin. The MS⁵ shows the M^+ peak at m/z 338 and the base peak at m/z 201; other significant fragments are at m/z 321 ($M^+ - OH$), 320 ($M^+ - H_2O$), 219 (A ring fragment - CH_3), 216 (A ring fragment - H_2O), and 104 (B ring fragment). The earlier authors⁵ did not explain the mass spectral data of falciformin with respect to their proposed structure 1. The distinctive difference in the MS of our synthetic 1 and natural falciformin⁵ was the cleavage of the alkyl side chain, whereas synthetic compound showed fragments (Chart I) with cleavage of the side chain, the natural compound (Chart II), had the side chain intact in most of the fragments because of the relative stability of the acetylenic function (in MS of 4) over the 1,3-diene system (in MS of 1) obtained by the elimination of a water molecule

(18) The base peak at m/z 201 is due to the formation of stable para quinonoid fragment a, which is feasible only in case the OMe function is at C-6 in falciformin. Also, the peak at m/z 267 (9)⁵ is probably misprint; it should be at m/z 277 and is due to the formation of stable fragment e as shown in Chart II. Such fragments are characteristic of flavonoids carrying a C-6 methoxy function.¹⁹

(19) (a) Dreyer, D. L. *J. Org. Chem.* **1968**, *33*, 3574. (b) *Ibid.* **1968**, *33*, 3577. (c) Parmar, V. S.; Jain, R.; Simonsen, R.; Boll, P. M. *Tetrahedron* **1987**, *43*, 4247.

from the respective molecular ion and "A ring fragments" of the two compounds; the mode of cleavage of the carbon framework of the C₅ side chain in 1 and 4 is also different. In light of the above observations, we propose structure 4, 2,3-dihydro-5-(1,1-dimethyl-2-hydroxyprop-2-enyl)-6-methoxy-2-phenyl-4H-1-benzopyran-4-one, for falciformin. To the best of our knowledge, this compound is not known in the literature and represents a novel structure among naturally occurring prenylated flavonoids.

Experimental Section

All melting points were determined on the H₂SO₄ bath and are uncorrected. Silica gel (BDH, 10–40 μm) was used for TLC, and silica gel (BDH, 60–120 mesh) was used for column chromatography. UV spectra were recorded on a Beckman DU-2 spectrophotometer, IR spectra on a Shimadzu Model 435 spectrophotometer; the NMR spectra were recorded on a Perkin-Elmer R-32 (90 MHz) or on a JEOL JNM FX-200 FT (200 MHz) NMR spectrometer with TMS as the internal standard and mass spectra were recorded on a Varian Mat 331 A instrument.

2,3-Dihydro-7-methoxy-8-(3-methylbut-2-enyl)-2-phenyl-4H-1-benzopyran-4-one (2). To a solution of 1-[2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-phenylprop-2-enone⁸ (0.36 g in 24 mL of alcohol) was added a solution of sodium acetate (0.24 g in 7 mL of water), the mixture was refluxed for 6 h, and it was diluted with water (50 mL) and extracted with chloroform (5 × 20 mL); removal of the solvent from the organic layer yielded the crude product. It was purified by preparative TLC (petroleum ether–benzene, 7:3) and crystallized from chloroform/petroleum ether as colorless needles (0.25 g): mp 104–5 °C; *R*_f²⁵ 0.60 (C₆H₆–CH₃CO₂C₂H₅, 9:1); gave a yellowish-red color with concentrated H₂SO₄; UV (MeOH) 310 (sh), 284, 235 (sh) nm; IR (Nujol) 1680, 1590, 1570, 1498, 1330, 1310, 1265, 1218, 1170, 1105, 1080, 900, 840, 700 cm⁻¹; ¹H NMR (CDCl₃) δ 1.60 (s, 6 H, 2 CH₃), 2.80–3.10 (m, 2 H, 2 H-3), 3.35 (d, *J* = 7 Hz, 2 H, 2 H-1''), 3.90 (s, 3 H, OCH₃), 5.18 (t, *J* = 7 Hz, 1 H, H-2''), 5.45 (q, 1 H, H-2), 6.66 (d, *J* = 9 Hz, 1 H, H-6), 7.35–7.55 (m, 5 H, B ring protons), 7.85 (d, *J* = 9 Hz, 1 H, H-5); ¹³C NMR (CDCl₃) δ 17.64 (C-5''), 22.07 (C-4''), 25.67 (C-1''), 44.32 (C-3), 55.76 (OCH₃), 79.27 (C-2), 105.0 (C-4a), 115.22 (C-8), 118.0 (C-6), 122.0 (C-5), 125.82 (C-3', C-5'), 126.18 (C-3''), 128.20 (C-2''), 128.76 (C-2', C-6'), 131.9 (C-4'), 139.5 (C-1'), 160.01 (C-8a), 163.19 (C-7), 191.26 (C-4); mass spectrum *m/z* (%) 323 (M + 1)⁺ (27), 322 (M⁺) (100), 321 (M – 1)⁺ (60), 307 (M⁺ – CH₃) (14), 279 (40), 267 (32), 217 (27), 218 (A ring fragment)⁺ (51), 203 (37), 190 (48), 175 (55), 163 (91), 131 (C₆H₅CH=CHCO)⁺ (30), 104 (B ring fragment)⁺ (23), 103 (18), 91 (27.3), 77 (C₆H₅)⁺ (18), 55 (C₄H₇)⁺ (9), 28 (39).

2,3-Dihydro-8-(2,3-epoxy-3-methylbutyl)-7-methoxy-2-phenyl-4H-1-benzopyran-4-one (3). To a stirred solution of 2 (0.26 g in 10 mL of dry chloroform) was added a solution of *m*-chloroperbenzoic acid (0.38 g in 30 mL of dry chloroform) dropwise during 0.5 h, with temperature being maintained between 0 and 5 °C, and the mixture was stirred at 25 °C for 24 h. The chloroform layer was thoroughly washed with aqueous sodium bicarbonate (1%) and dried over anhydrous sodium sulfate; evaporation of the organic layer yielded a light yellowish-brown oil from which 3 was obtained as a pale yellow oil (0.25 g; *R*_f²⁵ 0.44, C₆H₆–EtOAc, 9:1) by passing through a short column. It gave a yellowish-brown color with concentrated H₂SO₄; UV (MeOH) 235 (sh), 282, 317 (sh) nm; IR (Nujol) 1672, 1592, 1372, 1265, 1240, and 1100 cm⁻¹; ¹H NMR (CDCl₃) δ 1.25 (s, 6 H, 2 CH₃), 2.50–3.30 (m, 4 H, 2 H-1' and 2 H-3), 3.80–4.05 (m, 4 H, OCH₃ and H-2''), 5.20–5.85 (m, 1 H, H-2), 6.60 (d, *J* = 9 Hz, H-6), 7.35 (bs, 5 H, B ring protons), 7.85 (d, *J* = 9 Hz, H-5); ¹³C NMR (CDCl₃) δ 18.81 (C-5''), 22.55 (C-4''), 24.46 (C-1''), 44.50 (C-3), 56.0

(OCH₃), 59.50 (C-3''), 63.26 (C-2''), 79.50 (C-2), 105.0 (C-4a), 126.0 (C-8), 127.5 (C-6), 128.40 (C-5), 129.97 (C-3', C-5'), 133.65 (C-2', C-6'), 134.56 (C-4'), 138.70 (C-1'), 163.5 (C-8a), 170.46 (C-7), 191.41 (C-4); mass spectrum *m/z* (%) 339 (M + 1)⁺ (8.5), 338 (M⁺) (33.8), 323 (2), 295 (24.05), 280 (11.05), 267 (27.3), 234 (4), 193 (31.2), 192 (18.2), 191 (86.45), 177 (23.4), 176 (82.55), 175 (44.2), 164 (24.05), 163 (106), 161 (11.7), 156 (37.05), 148 (45.15), 141 (11.7), 139 (35.75), 133 (37.05), 131 (20.15), 120 (12.35), 111 (20.8), 105 (31.2), 104 (25.35), 103 (18.85), 92 (11.05), 91 (11.05), 78 (80.27), 77 (C₆H₅)⁺ (33.15), 75 (15.6), 73 (61.1), 71 (6), 65 (7.8), 59 (8.45), 51 (13.65), 50 (11.7). Anal. Calcd for C₂₁H₂₂O₄: C, 74.56; H, 6.51. Found: C, 74.01; H, 6.91.

2,3-Dihydro-8-(3-hydroxy-3-methylbut-1-enyl)-7-methoxy-2-phenyl-4H-1-benzopyran-4-one (1). In a dry 250-mL three-necked round-bottomed flask fitted with an effective reflux condenser, a dropping funnel, a rubber septum, a magnetic stirring bar, and a nitrogen inlet tube to maintain constant flow of dry nitrogen gas were placed dry diethyl amine (0.15 mL) and dry ether (15 mL). The flask was immersed in ice bath maintained at 0–5 °C, and *n*-butyllithium in hexane (1.4 M, 1 mL) was added carefully through the rubber septum by means of a syringe. After stirring for 10 min, a solution of 3 (0.3 g) in dry ether (7 mL) was added dropwise over a period of 30 min, and the mixture was stirred at 50 °C for 1 h, and the ether layer was washed successively with dilute hydrochloric acid (4 × 20 mL) followed by water (3 × 10 mL). The ether layer was then dried over anhydrous sodium sulfate, the solvent was removed, the resulting yellow-brown gummy solid was then purified by preparative TLC (C₆H₆–CH₃CO₂C₂H₅, 9:1), and the band having *R*_f²⁵ 0.23 yielded 1. It crystallized from petroleum ether–chloroform as colorless needles (0.2 g): mp 178–79 °C; gave a yellow color with concentrated H₂SO₄; UV (MeOH) 315, 232 (sh); +AlCl₃ 316, 228 (sh); +NaOMe 308; +NaOH 312, 226 (sh) nm; IR (Nujol) 3450, 1670, 1610, 1560, 1440, 1370, 1330, 1268, 1230, 1200, 1110, 1080, 975, and 760 cm⁻¹; ¹H NMR (CDCl₃) δ 1.29 and 1.42 (2 s, 6 H, 2 CH₃), 1.75 (bs, 1 H, OH), 2.80–3.55 (m, 2 H, 2 H-3), 3.85 (s, 3 H, OCH₃), 4.30–5.55 (m, 2 H, H-2, H-2''), 6.32 (d, *J* = 9 Hz, 1 H, H-6), 7.00–7.90 (m, 7 H, H-1'', H-5 and B ring protons); ¹³C NMR (CDCl₃) δ 26.48 (C-5''), 27.50 (C-4''), 49.20 (C-3), 55.52 (OCH₃), 71.52 (C-2), 91.21 (C-3''), 104.12 (C-4a), 125.80 (C-8), 128.17 (C-3', C-5'), 128.67 (C-2''), 129.0 (C-2', C-6'), 129.04 (C-1''), 130.01 (C-6), 131.67 (C-5), 142.50 (C-4'), 144.30 (C-1'), 160.50 (C-8a), 163.05 (C-7), 192.25 (C-4); mass spectrum *m/z* (%) 339 (17), 338 (18), 337 (46), 323 (4), 321 (5), 280 (68), 279 (34), 265 (30), 235 (39), 220 (7), 217 (12), 202 (16), 192 (19), 176 (24), 175 (29), 174 (20), 163 (15), 161 (100), 148 (18), 133 (19), 131 (34), 105 (18), 103 (26), 77 (20), 73 (45), 58 (24), 55 (14), 41 (14), 28 (13), 18 (17), 15 (4). Anal. Calcd for C₂₁H₂₂O₄: C, 74.56; H, 6.51. Found: C, 73.92; H, 6.98.

UV data of a natural sample of falciformin:⁵ UV (MeOH) 260 and 290 nm; no shift with alkali; shifts with other reagents not reported.

UV data as recorded by us of a natural specimen of falciformin:⁵ UV (MeOH) 230, 258, 290 nm; +AlCl₃ 218, 260 (sh), 282, 312 (sh), 358; +NaOH 230, 260, 325 nm; +NaOMe 254 (sh), 274, 290, 322, 400 nm.

Acknowledgment. We sincerely thank Dr. H. A. Khan (Central Arid Zone Research Institute, Jodhpur, 342 003, India) for kindly sending a small sample of natural falciformin and our colleague Dr. S. C. Jain for helpful discussions in arriving at the structure 4. Two of us (S.G. and V.K.S.) thank the CSIR (New Delhi) for financial assistance.

Registry No. 1, 124439-13-0; 2, 124355-21-1; 3, 124355-22-2; 4, 102275-31-0; 1-[2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-phenylprop-2-enone, 34211-25-1.